市場調查報告書
商品編碼
1415024
非專利藥注射劑市場:按產品類型、應用、分銷管道分類 - 2024-2030 年全球預測Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年非專利藥市場規模將達300億美元,預計2024年將達331.2億美元,2030年將達到606.6億美元,複合年成長率為10.57%。
全球非專利藥注射劑市場
主要市場統計 | |
---|---|
基準年[2023] | 300億美元 |
預測年份 [2024] | 331.2億美元 |
預測年份 [2030] | 606.6億美元 |
複合年成長率(%) | 10.57% |
非專利藥注射劑是透過注射給藥的非品牌藥物,具有與品牌產品相同的活性成分、規格、劑型、給藥途徑、品質、性能特徵和預期用途。它通常在原廠產品的專利到期後出售。非專利藥注射劑透過提供具有成本效益的品牌藥物替代品,有助於節省醫療費用並為患者提供便利。對更實惠的藥物的需求不斷成長,以及由於幾種品牌注射劑的專利到期而導致學名藥進入市場,推動了學名藥注射劑市場的發展。世界各國政府的成本控制政策也支持廣泛普及具有成本效益的非專利注射劑。此外,需要注射藥物治療的慢性疾病的增加也支持了市場的成長。儘管成長前景廣闊,但市場在維持高品質標準方面面臨挑戰,如果管理不當,可能會導致召回和聲譽受損。此外,市場競爭激烈且價格下降,這可能會阻礙非專利注射劑的採用。然而,研究重點是先進的藥物輸送系統、生物相似藥開發、永續生產以及提高產品穩定性和保存期限的配方進步,為市場擴張提供了利潤豐厚的機會。
區域洞察
美國尤其是美國的非專利藥注射劑市場正在經歷顯著成長。由於學名藥到期、政府努力最大限度地降低醫療成本以及慢性病的增加,該地區對負擔得起的專利到期藥的需求正在迅速增加。除了發達的醫療保健產業外,美洲地區也受惠於競爭激烈的市場形勢,許多參與企業不斷致力於推出新產品和具成本效益的製造流程。歐洲、中東和非洲(Europe, Middle East, and Africa)地區的非專利注射藥物市場正在穩步成長。這一業績是由旨在促進學名藥使用和對生物相似藥的重視的政府支持性衛生政策所推動的。雖然歐洲市場尤其受益於確保高品質產品的嚴格監管標準,但成本效益仍然是非專利注射劑普及的驅動力。隨著醫療基礎設施的改善和藥物取得的增加,中東和非洲的市場正在穩步發展。目前非專利學名藥領域在亞太地區正在迅速擴張。印度和中國因其龐大的人口基數、不斷上漲的醫療成本以及政府對學名藥生產的支持政策而成為這一成長的主要貢獻者。該地區還擁有大量學名藥生產商,支持了當地市場的成長。此外,慢性病盛行率的不斷上升以及新興國家加強醫療保健系統的共同努力,為亞太地區非專利藥注射劑市場的成長奠定了堅實的基礎。
FPNV定位矩陣
FPNV 定位矩陣對於評估非專利注射劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對非專利注射劑市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴考察,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1-市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2-市場開拓:我們深入研究利潤豐厚的新興市場,並分析它們在成熟細分市場中的滲透率。
3- 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4-競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5- 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1-非專利注射劑市場的市場規模和預測是多少?
2-在非專利藥市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3-非專利藥注射劑市場的技術趨勢和法律規範是什麼?
4-非專利藥市場主要供應商的市場佔有率是多少?
5-進入非專利注射藥市場的合適型態和策略手段是什麼?
[187 Pages Report] The Generic Injectables Market size was estimated at USD 30.00 billion in 2023 and expected to reach USD 33.12 billion in 2024, at a CAGR 10.57% to reach USD 60.66 billion by 2030.
Global Generic Injectables Market
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 30.00 billion |
Estimated Year [2024] | USD 33.12 billion |
Forecast Year [2030] | USD 60.66 billion |
CAGR (%) | 10.57% |
Generic injectables are non-branded pharmaceuticals that are administered by injection and have the same active ingredients, strength, dosage form, route of administration, quality, performance characteristics, and intended use as their branded counterparts. They are typically marketed after the original branded product's patent protection has expired. Generic injectables offer a cost-effective alternative to brand-name drugs, thereby contributing to healthcare savings and increased accessibility for patients. The generic injectables market is fueled by the increasing demand for more affordable pharmaceuticals and the expiration of patents for multiple branded injectables, which allows generic versions to enter the market. Cost-containment policies by governments worldwide also drive the uptake of cost-effective generic injectables. In addition, the rise in the prevalence of chronic diseases that require injectable drugs for treatment supports the market growth. Despite the promising growth, the market faces challenges due to maintaining high-quality standards, which, if not adequately managed, can lead to recalls and reputational damage. Furthermore, the market is subject to intense competition and price erosion, which can hinder the adoption of generic injectables. However, research focusing on advanced drug delivery systems, biosimilar development, sustainable production, and formulation advancements to improve product stability and storage presents lucrative opportunities for market expansion.
Regional Insights
The market for generic injectables in the Americas, and particularly in the United States, has seen significant growth. The expiration of patents for branded drugs, government initiatives to minimize healthcare costs, and the rising prevalence of chronic diseases have resulted in a surging need for affordable generic alternatives in this region. The Americas region benefits from a well-developed healthcare sector and a competitive market landscape where numerous players are constantly engaged in the introduction of new products and cost-effective manufacturing processes. The Europe, Middle East, and Africa (EMEA) region has experienced steady growth in the generic injectables market. This performance is facilitated by supportive governmental health policies aimed at promoting the use of generics, as well as an emphasis on biosimilars. The European market, in particular, benefits from stringent regulatory standards that ensure high-quality products, while cost-effectiveness remains a driving factor behind the widespread adoption of generic injectables. In the Middle East and Africa, the market is steadily evolving with the improving healthcare infrastructure and increased accessibility to medication. The Asia-Pacific (APAC) region is currently witnessing rapid expansion in the generic injectables sector. India and China, with their vast population base, increasing healthcare expenditure, and supportive government policies for generic medicine production, are contributing significantly to this growth. The region also hosts a significant number of generic drug manufacturers, which bolster the local market growth. Additionally, the growing incidence of chronic conditions, coupled with a concerted effort to enhance healthcare systems in emerging economies, provides a robust platform for the growth of the generic injectables market in APAC.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Generic Injectables Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Injectables Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eugia US LLC, Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Generic Injectables Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Injectables Market?
3. What are the technology trends and regulatory frameworks in the Generic Injectables Market?
4. What is the market share of the leading vendors in the Generic Injectables Market?
5. Which modes and strategic moves are suitable for entering the Generic Injectables Market?